This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Liu, Y.-H. Articles by Carretero, O. A. Search for Related Content PubMed PubMed Citation Articles by Liu, Y.-H. Articles by Carretero, O. A. Related Collections Cardiovascular Pharmacology ACE/Angiotension receptors Animal models of human disease Genetically altered mice Heart failure - basic studies Endothelium/vascular type/nitric oxide

(Hypertension. 2002;39:375.)
© 2002 American Heart Association, Inc.

Scientific Contributions

Effect of ACE Inhibitors and Angiotensin II Type 1 Receptor Antagonists on Endothelial NO Synthase Knockout Mice With Heart Failure

Yun-He Liu; Jiang Xu; Xiao-Ping Yang; Fang Yang; Edward Shesely; Oscar A. Carretero

From the Hypertension and Vascular Research Division, Department of Internal Medicine, Henry Ford Hospital, Detroit, Mich.

Correspondence to Oscar A. Carretero, MD, Division Head, Hypertension and Vascular Research Division, Henry Ford Hospital, 2799 West Grand Blvd, Detroit MI 48202-2689. E-mail ocarre+1{at}hfhs.org

The beneficial effects of ACE inhibitors (ACEi) or angiotensin II type 1 receptor antagonists (AT₁-ant) are reportedly mediated by NO in heart failure (HF). We hypothesized that in the absence of endothelial NO synthase (eNOS), (1) left ventricular (LV) dysfunction and myocardial remodeling would be more severe after myocardial infarction (MI), and (2) the cardioprotective effect of ACEi and AT₁-ant would be diminished or absent in mice with HF after MI. eNOS knockout mice (eNOS-/-) and wild-type C57BL/6J (C57) mice (+/+) were subjected to MI by ligating the left coronary artery. One month after MI, each strain was treated with vehicle, ACEi (enalapril, 20 mg/kg per day), or AT₁-ant (valsartan, 50 mg/kg per day) for 5 months. Echocardiography was performed, and systolic blood pressure was measured before MI and monthly thereafter. Interstitial collagen fraction and myocyte cross-sectional area were examined histologically. We found that (1) compared with C57 mice, eNOS-/- mice that underwent sham surgery had significantly increased systolic blood pressure (P<0.05) and increased LV mass both initially and at 1 to 3 months, although cardiac function and histological findings did not differ between strains; (2) the development of HF and myocardial remodeling were similar after MI in both strains; and (3) ACEi improved cardiac function and remodeling in C57 mice, as evidenced by increased LV ejection fraction (LVEF) and LV shortening fraction (LVSF) and decreased diastolic LV dimension, mass, myocyte cross-sectional area, and interstitial collagen fraction, but these benefits were absent or diminished in eNOS-/- mice (for C57 versus eNOS-/-: increase in LVEF after ACEi, 14.2±2% versus -4.9±2.5%, respectively [P<0.001]; increase in LVSF, 8.6±2.1% versus -7.2±2.8%, respectively [P<0.01]; and decrease in LV mass, -16.6±15 versus 73±23 mm³, respectively [P<0.01]). AT₁-ant had benefits similar to those of ACEi, which were also absent or diminished in eNOS-/- mice (for C57 versus eNOS-/-: increase in LVEF after AT₁-ant, 13.5±1.8% versus -9.8±3%, respectively [P<0.001]; increase in LVSF, 6.1±1.6% versus -3.8±3.1%, respectively [P<0.01]). Our data suggest that the absence of NO does not alter the development of HF after MI; however, it significantly decreases the cardioprotective effects of ACEi or AT₁-ant.

Key Words: nitric oxide • nitric oxide synthase • heart failure • angiotensin-converting enzyme inhibitors • receptors, angiotensin II • mice

This article has been cited by other articles:

				K.-H. Su, J.-Y. Tsai, Y. R. Kou, A.-N. Chiang, S.-H. Hsiao, Y.-L. Wu, H.-H. Hou, C.-C. Pan, S.-K. Shyue, and T.-S. Lee Valsartan regulates the interaction of angiotensin II type 1 receptor and endothelial nitric oxide synthase via Src/PI3K/Akt signalling Cardiovasc Res, June 1, 2009; 82(3): 468 - 475. [Abstract] [Full Text] [PDF]

				J. R. Somers, P. L. Beck, J. P. Lees-Miller, D. Roach, Y. Li, J. Guo, S. Loken, S. Zhan, L. Semeniuk, and H. J. Duff iNOS in cardiac myocytes plays a critical role in death in a murine model of hypertrophy induced by calcineurin Am J Physiol Heart Circ Physiol, September 1, 2008; 295(3): H1122 - H1131. [Abstract] [Full Text] [PDF]

				D. Fraccarollo, J. D. Widder, P. Galuppo, T. Thum, D. Tsikas, M. Hoffmann, H. Ruetten, G. Ertl, and J. Bauersachs Improvement in Left Ventricular Remodeling by the Endothelial Nitric Oxide Synthase Enhancer AVE9488 After Experimental Myocardial Infarction Circulation, August 19, 2008; 118(8): 818 - 827. [Abstract] [Full Text] [PDF]

				P. L. Diaz-Sylvester, M. C. Fiori, S. M. Dieguez, A. C. Muller, M. L. Lopardo, and C. E. Amorena Effect of chronic inhibition of converting enzyme on proximal tubule acidification Am J Physiol Regulatory Integrative Comp Physiol, June 1, 2008; 294(6): R2014 - R2020. [Abstract] [Full Text] [PDF]

				M. Seddon, A. M. Shah, and B. Casadei Cardiomyocytes as effectors of nitric oxide signalling Cardiovasc Res, July 15, 2007; 75(2): 315 - 326. [Abstract] [Full Text] [PDF]

				T.-M. Lee, M.-S. Lin, C.-H. Tsai, and N.-C. Chang Effect of pravastatin on left ventricular mass in the two-kidney, one-clip hypertensive rats Am J Physiol Heart Circ Physiol, December 1, 2006; 291(6): H2705 - H2713. [Abstract] [Full Text] [PDF]

				B. Casadei The emerging role of neuronal nitric oxide synthase in the regulation of myocardial function Exp Physiol, November 1, 2006; 91(6): 943 - 955. [Abstract] [Full Text] [PDF]

				H. Post and B. Pieske Arginase: a modulator of myocardial function Am J Physiol Heart Circ Physiol, May 1, 2006; 290(5): H1747 - H1748. [Full Text] [PDF]

				D. Dawson, C. A. Lygate, M.-H. Zhang, K. Hulbert, S. Neubauer, and B. Casadei nNOS Gene Deletion Exacerbates Pathological Left Ventricular Remodeling and Functional Deterioration After Myocardial Infarction Circulation, December 13, 2005; 112(24): 3729 - 3737. [Abstract] [Full Text] [PDF]

				T.-M. Lee, M.-S. Lin, T.-F. Chou, C.-H. Tsai, and N.-C. Chang Effect of pravastatin on development of left ventricular hypertrophy in spontaneously hypertensive rats Am J Physiol Heart Circ Physiol, July 1, 2005; 289(1): H220 - H227. [Abstract] [Full Text] [PDF]

				H. Ruetten, S. Dimmeler, D. Gehring, C. Ihling, and A. M. Zeiher Concentric left ventricular remodeling in endothelial nitric oxide synthase knockout mice by chronic pressure overload Cardiovasc Res, June 1, 2005; 66(3): 444 - 453. [Abstract] [Full Text] [PDF]

				G. W. Booz Putting the Brakes on Cardiac Hypertrophy: Exploiting the NO-cGMP Counter-Regulatory System Hypertension, March 1, 2005; 45(3): 341 - 346. [Abstract] [Full Text] [PDF]

				A. L. Taylor, S. Ziesche, C. Yancy, P. Carson, R. D'Agostino Jr., K. Ferdinand, M. Taylor, K. Adams, M. Sabolinski, M. Worcel, et al. Combination of Isosorbide Dinitrate and Hydralazine in Blacks with Heart Failure N. Engl. J. Med., November 11, 2004; 351(20): 2049 - 2057. [Abstract] [Full Text] [PDF]

				O. Johren, A. Dendorfer, and P. Dominiak Cardiovascular and renal function of angiotensin II type-2 receptors Cardiovasc Res, June 1, 2004; 62(3): 460 - 467. [Abstract] [Full Text] [PDF]

				S. D. Prabhu Nitric Oxide Protects Against Pathological Ventricular Remodeling: Reconsideration of the Role of NO in the Failing Heart Circ. Res., May 14, 2004; 94(9): 1155 - 1157. [Full Text] [PDF]

				D. N. Granger, T. Vowinkel, and T. Petnehazy Modulation of the Inflammatory Response in Cardiovascular Disease Hypertension, May 1, 2004; 43(5): 924 - 931. [Abstract] [Full Text] [PDF]

				A. Schafer, D. Fraccarollo, P. Tas, I. Schmidt, G. Ertl, and J. Bauersachs Endothelial dysfunction in congestive heart failure: ACE inhibition vs. angiotensin II antagonism Eur J Heart Fail, March 1, 2004; 6(2): 151 - 159. [Abstract] [Full Text] [PDF]

				F. Ichinose, K. D. Bloch, J. C. Wu, R. Hataishi, H. T. Aretz, M. H. Picard, and M. Scherrer-Crosbie Pressure overload-induced LV hypertrophy and dysfunction in mice are exacerbated by congenital NOS3 deficiency Am J Physiol Heart Circ Physiol, March 1, 2004; 286(3): H1070 - H1075. [Abstract] [Full Text] [PDF]

				C. M. Bove, Z. Yang, W. D. Gilson, F. H. Epstein, B. A. French, S. S. Berr, S. P. Bishop, H. Matsubara, R. M. Carey, and C. M. Kramer Nitric Oxide Mediates Benefits of Angiotensin II Type 2 Receptor Overexpression During Post-Infarct Remodeling Hypertension, March 1, 2004; 43(3): 680 - 685. [Abstract] [Full Text] [PDF]

				D. Fraccarollo, P. Galuppo, S. Hildemann, M. Christ, G. Ertl, and J. Bauersachs Additive improvement of left ventricular remodeling and neurohormonal activation by aldosterone receptor blockade with eplerenone and ACE inhibition in rats with myocardial infarction J. Am. Coll. Cardiol., November 5, 2003; 42(9): 1666 - 1673. [Abstract] [Full Text] [PDF]

				A. H. Schmaier The kallikrein-kinin and the renin-angiotensin systems have a multilayered interaction Am J Physiol Regulatory Integrative Comp Physiol, July 1, 2003; 285(1): R1 - R13. [Abstract] [Full Text] [PDF]

				M. Obst, V. Gross, J. Janke, M. Wellner, W. Schneider, and F. C. Luft Pressure Natriuresis in AT2 Receptor-Deficient Mice with L-NAME Hypertension J. Am. Soc. Nephrol., February 1, 2003; 14(2): 303 - 310. [Abstract] [Full Text] [PDF]

				P B Massion and J-L Balligand Modulation of cardiac contraction, relaxation and rate by the endothelial nitric oxide synthase (eNOS): lessons from genetically modified mice J. Physiol., January 1, 2003; 546(1): 63 - 75. [Abstract] [Full Text] [PDF]